Report

The Acne Therapeutics Market was valued at USD 7,679.27 million in 2021 and is projected to register a CAGR of 4.67% during the forecast period of 2022-2027.

The COVID-19 pandemic is expected to have a significant impact on the market. In the context of COVID-19, government organizations in various countries, research institutes, and many biotech and pharmaceutical firms are focusing on developing effective and rapid technologies for the fast diagnosis of COVID-19 and developing vaccines/new therapeutics to overcome the current situation. The primary reason is associated with a lack of resources and patients. In addition, the market players cannot put more burden about clinical trials and manufacturing of the already approved drugs, as healthcare facilities are already overburdened with the COVID-19 crisis in recent times. Moreover, the North American market was also adversely affected by the pandemic. For instance, a study published in November 2021 in the National Library of Medicine titled "The impact of COVD-19 on North American dermatology practices" reported decreased patient volume capacity, fewer aesthetic and surgical procedures, and an increase in the use of virtual medicine among board-certified North American dermatologists. ?

The key factors are propelling the growth of the acne therapeutics market are increasing sedentary lifestyles and unhealthy lifestyles, the rise in disposable income of consumers, raising awareness about upcoming trends in acne treatments, and the high prevalence of acne globally.

Acne is the most common skin condition affecting late adolescents across the world. Acne vulgaris is a common heath problem affecting adolescents with a considerable impact on their quality of life. For instance, the study published in the Journal of Egyptian Public Health Association article titled 'Acne vulgaris: prevalence, severity, and impact on quality of life and self-esteem among Egyptian adolescents,' published in November 2020, reported that the prevalence of self-reported acne was 34.7% in studied Egyptian population. The same source also said that the majority of clinically confirmed acne was 24.4%, with higher rates among females (28.6%) than males (20.2%). Additionally, the study found that most students (75.5%) had mild acne.? The rising prevalence of acne will lead to increased adoption of acne therapeutics, thereby driving the market's growth.

Furthermore, in March 2021, Galderma launched a new digital campaign. "Me Being Me" for topical acne treatment with Aklief (trifarotene) Cream. Aklief received Food and Drug Administration approval in 2019, with Galderma's efforts targeting patients in early 2020. The company spent much of the year educating patients about Aklief, which is the first new retinoid molecule to gain approval for acne vulgaris in more than 20 years. Such initiatives provide insight into the upcoming treatment for acne. These campaigns increase the growth of the market during the forecast period.

Thus, the high prevalence of acne among the global population and the rise in awareness on acne treatment is expected to drive the market during the forecast period. However, safety issues related to acne products and the entry of generics into the acne market are expected to hinder the market growth.

Acne Therapeutics Market Trends

Retinoid Segment is Expected to Hold a Major Share in Acne Therapeutics Market.

The retinoid segment is expected to hold a significant share in the acne therapeutics market. Retinoid creams and gels are very effective at stopping or reducing mild to moderate acne; therefore, this segment has increased demand. They can also be used as maintenance therapy to keep skin clear after successful treatment. Additionally, market players frequently launch novel and generic versions of retinoids to gain a competitive edge in the market. For instance, in February 2022, Stryke Club launched retinoid acne treatment with its Knockout Adapalene Gel that prevents pimples, blackheads, whiteheads, and clogged pores. Food and Drug AdminiAdministration-approved prescription-strength retinoid acne treatment, available without a prescription.? The rising product launches of retinoid treatment will lead to increased adoption due to its benefits in treating acne, thereby expected to drive the growth of this segment.

Furthermore, an increase in research and development for retired acne therapies will also contribute to the growth of this market over the forecast period. For instance, in April 2021, Bausch Health's prescription dermatology subsidiary Ortho Dermatologics announced positive topline data from its second Phase III trial for IDP-126, a three-compound combination gel tested in 193 patients with acne vulgaris, showing reductions in both inflammatory and non-inflammatory lesions at week 12 in both problems. IDP-126 combines adapalene, retinol, and anti-microbial benzoyl peroxide. Such research around the products and combination of retinoids are expected to increase the sales and manufacturing of the same boosting the segment growth.

Therefore, owing to the above factors, the retinol segment is expected to show a significant share during the forecast period.

North America Holds a Significant Market Share and Expected to do the Same in the Forecast Period

The growing burden of acne in the region and recent product launches are the primary driving factors for the growth of the acne therapeutics market in North America. Many key market players in the area are developing novel products and technologies, competing with the existing products, while others are acquiring and partnering with the other companies trending in the acne therapeutics market. For instance, in November 2021, Winlevi (Clascoterone cream 1%) by Sun Pharmaceuticals, the first-in-class topical therapy for acne vulgaris, was launched in the United States. The rising product launches in developed countries such as the United States will lead to increased adoption, thereby expected to drive the growth in North America.

Furthermore, rising research and development with positive results in acne treatment is also expected to drive the growth of this segment over the forecast period. For instance, in June 2020, Menlo Therapeutics Inc., a United States-based dermatological therapeutics producer, announced positive results from a Phase 2 clinical trial evaluating the preliminary safety and efficacy of FCD105 (3% minocycline/0.3% adapalene foam), the first-ever topical minocycline-based combination product, for the treatment of moderate-to-severe acne vulgaris. Such research studies are driving the growth of the market in the region.

Thus, the frequent product launches and research and development activities undergoing the development of novel acne therapies are expected to drive the market studied in the North American region.

Acne Therapeutics Market Competitor Analysis

The acne therapeutics market is highly competitive and consists of several major and local players. The market is expected to drive due to the rise in research on acne treatment and product approvals for acne treatment, among others. Some major players in this market include Abbvie Inc. (Allergan PLC), JOHNSON & JOHNSON, L'Oreal S.A. (La Roche-Posay Laboratoire Dermatologique), Teva Pharmaceuticals, and Sun Pharmaceutical Industries, Inc., amongst others.

Additional Benefits:

The market estimate (ME) sheet in Excel format
3 months of analyst support